ImmunityBio Shares Advance as Company Addresses Regulatory Concerns

ImmunityBio shares gain as the firm removes disputed marketing materials and implements new compliance training to address FDA warnings over its bladder cancer drug.

ImmunityBio's stock moved higher this week as the biotechnology firm took concrete steps to address a recent warning from the U.S. Food and Drug Administration (FDA). The regulatory body had criticized the company for promotional claims deemed misleading related to its bladder cancer therapy, Anktiva. In response, ImmunityBio has initiated a comprehensive compliance overhaul, which includes removing contentious marketing materials. Investors welcomed the decisive action aimed at mitigating regulatory risk.

A Strategic Pivot to Compliance

The FDA's reprimand in mid-March centered on allegations of unsubstantiated efficacy claims. A particular point of contention was a podcast featuring the company’s Executive Chairman, Dr. Patrick Soon-Shiong. ImmunityBio confirmed this week that it has deleted this content from all public platforms. Company management also clarified that a television commercial flagged by regulators was never actually broadcast.

To prevent future disputes, the firm is now implementing mandatory training programs for its leadership and will subject future marketing campaigns to review by external consultants. This proactive stance appears to have reassured the market. On Monday, shares gained 3%, solidifying a remarkable year-to-date increase of more than 250%. This valuation surge is underpinned by robust commercial performance; net revenue for Anktiva soared by approximately 700% to $113 million in 2025.

Market analysts continue to see significant potential for the drug, maintaining bullish ratings:
* Piper Sandler: Rates the equity "Overweight" with a $12 price target.
* BTIG: Issues a "Buy" recommendation and a $13 price target.

Legal Challenges and Pipeline Progress

Despite operational successes, ImmunityBio faces ongoing legal headwinds. Several law firms are pursuing class-action lawsuits, alleging that misleading statements by management contributed to a $2 billion loss in market value in late March. The lead plaintiff deadline for these proceedings is set for May 26, 2026.

Concurrently, the company is advancing its clinical development pipeline. Patient recruitment for the QUILT-2.005 study is now complete. A potential regulatory submission for this expanded bladder cancer indication is tentatively planned for late 2026. Further trials are underway exploring the application of the company's therapy in lung and pancreatic cancers.